Compared with CHIP, CCUS has an overlapping mutational landscape, an approximate 10‐fold lower incidence, higher clonal size and clonal complexity and an increased risk of progression to myeloid neoplasia (MN—encompassing acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms) compared to CHIP [12, 13, 14], suggesting that CCUS likely represents a developmental intermediate state between CHIP and MN. Here, STUB1 is linked to myeloproliferative disorder.